CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer.
Melissa L. Johnson(Tennessee Oncology), Alexander I. Spira(Virginia Cancer Specialists), Rachel E. Sanborn(Providence Portland Medical Center), Navid Hafez(Smilow Cancer Hospital), Anthony B. El-Khoueiry(USC Norris Comprehensive Cancer Center), Hirva Mamdani(Wayne State University), Jana Waldes(CytomX Therapeutics (United States)), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Thang Ho(CytomX Therapeutics (United States)), Rachel Li(CytomX Therapeutics (United States))
Cited by 18
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k